Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 6/20 | 0.39 |
| ▸ | MMP9 | P14780 | 6/20 | 0.39 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | MMP14 | P50281 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2274359 | 0.92 | L3MBTL1 (0.41) | L3MBTL1MAPTMMP2MMP9ADAM10 | |
| Trifluoroacetic Acid SCHEMBL4385494 | 0.91 | ITGB3 (0.44) | L3MBTL1MAPTMMP2MMP9ADAM10 | |
| Trifluoroacetic Acid SCHEMBL27589878 | 0.91 | ITGB3 (0.44) | L3MBTL1MAPTMMP2MMP9ADAM10 | |
| SCHEMBL24136485 | 0.90 | CA1 (0.42) | L3MBTL1MAPTMMP2MMP9ADAM10 | |
| SCHEMBL8313275 | 0.90 | CA1 (0.42) | L3MBTL1MAPTMMP2MMP9ADAM10 | |
| SCHEMBL17911909 | 0.90 | CA1 (0.42) | L3MBTL1MAPTMMP2MMP9ADAM10 | |
| SCHEMBL2274363 | 0.90 | L3MBTL1 (0.40) | L3MBTL1MAPTMMP2MMP9ADAM10 | |
| SCHEMBL4960020 | 0.89 | MMP2 (0.47) | L3MBTL1MAPTMMP2MMP9ADAM10 | |
| SCHEMBL19809645 | 0.89 | MMP2 (0.47) | L3MBTL1MAPTMMP2MMP9ADAM10 | |
| SCHEMBL4653743 | 0.87 | SMN1; SMN2 (0.42) | L3MBTL1MAPTMMP2MMP9ADAM10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622647-B1 | VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS AND THEIR USE IN THE PREPARATION OF RADIOPHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | KEREOS, INC. | 2008-12-11 | — | — | US | disclosed |
| EP-1307226-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MEDICAL IMAGING INC (US) | 2008-11-19 | — | — | EP | disclosed |
| US-7332149-B1 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-02-19 | — | — | US | disclosed |
| US-7321045-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1140203-B1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7138104-B2 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060217292-A1 | Vitronectin receptor antagonist compounds and their use in the preparation of diopharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2006-09-28 | — | — | US | disclosed |
| US-7018611-B2 | Vitronectin receptor antagonist pharmaceuticals | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-03-28 | — | — | US | disclosed |
| EP-1622647-A1 | VITRONECTIN RECEPTOR ANTAGONIST COMPOUNDS AND THEIR USE IN THE PREPARATION OF RADIOPHARMACEUTICALS | Bristol-Myers Squibb Pharma Company (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2003-12-18 | — | — | US | disclosed |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS HOLDINGS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | LANTHEUS MEDICAL IMAGING, INC. | 2003-06-05 | — | — | US | disclosed |
| EP-1311301-A2 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | Bristol-Myers Squibb Pharma Company (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6511648-B2 | Diagnosis, therapy cancer | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-28 | — | — | US | disclosed |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | LANTHEUS MI REAL ESTATE, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020122768-A1 | Stable radiopharmaceutical compositions and methods for preparation thereof | LANTHEUS MEDICAL IMAGING, INC. | 2002-09-05 | — | — | US | disclosed |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MI REAL ESTATE, LLC | 2002-05-23 | — | — | US | disclosed |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-04-11 | — | — | US | disclosed |
| WO-2002004030-A2 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030103898-A1 | Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent | TNNI3, ASGR1, TNNT2 | L3MBTL1 3874/4885MAPT 3050/4885MMP2 2824/4885 |
| US-20080305037-A1 | LINKERS FOR ANCHORING TARGETING LIGANDS | LDLR, HDLBP, FABP1 | L3MBTL1 512/4885MAPT 2077/4885MMP2 4079/4885 |
| US-20060217292-A1 | Vitronectin receptor antagonist compounds and their use in the preparation of diopharmaceuticals | TEK, KDR, EDNRA | L3MBTL1 4672/4885MAPT 2569/4885MMP2 2198/4885 |
| US-20020041878-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | L3MBTL1 3077/4885MAPT 4562/4885MMP2 2243/4885 |
| US-20020122768-A1 | Stable radiopharmaceutical compositions and methods for preparation thereof | AHR, PAH, TYR | L3MBTL1 4118/4885MAPT 587/4885MMP2 4261/4885 |
| US-20030232053-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | L3MBTL1 2840/4885MAPT 4584/4885MMP2 2373/4885 |
| US-20030113336-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | L3MBTL1 3077/4885MAPT 4562/4885MMP2 2243/4885 |
| US-20020061909-A1 | Vitronectin receptor antagonist pharmaceuticals | ADGRF1, RXFP1, VCAM1 | L3MBTL1 2840/4885MAPT 4584/4885MMP2 2373/4885 |
| US-20020182147-A1 | VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS | ADGRF1, RXFP1, VCAM1 | L3MBTL1 2840/4885MAPT 4584/4885MMP2 2373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.